Xilio Therapeutics(XLO) GlobeNewswire·2025-01-21 22:05Core Insights - Xilio Therapeutics announced a preliminary response rate of 27% in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) who do not have liver metastases, indicating potential efficacy of the combination therapy [1][4] - The combination of vilastobart (XTX101) and atezolizumab (Tecentriq) demonstrated a differentiated safety profile with low incidence of immune-related adverse events [1][7] - The company plans to present further data at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium [1][2] Clinical Trial Data - As of January 13, 2025, 40 patients were treated with vilastobart at a dose of 100 mg every six weeks and atezolizumab at 1200 mg every three weeks, with a median age of 55 years [3] - Among patients without liver metastases, the objective response rate was 27%, with three partial responses reported [4][5] - The preliminary disease control rate was 55% for patients without liver metastases and 14% for those with liver metastases [6] Safety Profile - The combination therapy was generally well-tolerated, with only 5% of patients reporting colitis and a low incidence of immune-related adverse events [7][9] - Common treatment-related adverse events included fatigue (30%), diarrhea (20%), and infusion-related reactions (13%) [9] Future Development Plans - Xilio plans to report updated Phase 2 data in mid-2025 and is exploring opportunities for partnerships to expand development beyond the initial trial [10][11] - The ongoing Phase 1C dose escalation trial is evaluating vilastobart at a 150 mg dose level in combination with atezolizumab [11] Company Overview - Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [14]